Form 4: TherapeuticsMD Director Granted 8,500 Restricted Stock Units

TherapeuticsMD Director Cooper C. Collins was granted 8,500 Restricted Stock Units, which will vest on November 3, 2028.

Summary

• Cooper C. Collins, a Director of TherapeuticsMD, Inc. (TXMD), acquired 8,500 Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of common stock of TherapeuticsMD, Inc.
• The RSUs have a conversion or exercise price of $0, which is typical for such grants.
• The granted RSUs are scheduled to vest on November 3, 2028.
• Following this transaction, Cooper C. Collins beneficially owns 8,500 derivative securities (RSUs).

Sentiment

Score: 6

Explanation: The filing reports a routine equity grant to a director, which is generally viewed as a positive for aligning management incentives with shareholder interests, but it is not a significant market-moving event.

Positives

• The grant of Restricted Stock Units to a director aligns the director's interests with those of the shareholders, as the value of the compensation is tied to the company's stock performance.
• Equity compensation is a standard practice for attracting and retaining qualified board members.

Future Outlook

The 8,500 Restricted Stock Units granted to Director Cooper C. Collins are scheduled to vest on November 3, 2028, at which point they will convert into shares of common stock.

Industry Context

The grant of Restricted Stock Units to a director is a common form of equity compensation within the pharmaceutical and biotechnology industries, used to incentivize long-term performance and align leadership interests with shareholder value.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to a director is a standard practice for non-cash compensation across publicly traded companies, including those in the pharmaceutical sector.
• The $0 conversion price for RSUs is typical, as the value to the recipient is derived from the market price of the underlying common stock at the time of vesting, rather than an exercise price.

Related Party Transactions

• The acquisition of 8,500 Restricted Stock Units by Cooper C. Collins, a Director of TherapeuticsMD, Inc., constitutes a transaction with a related party (an insider). This is a standard form of equity compensation for board members.

Stakeholder Impact

• Shareholders: The grant of RSUs aligns the director's long-term interests with shareholder value creation. Upon vesting, there will be a minor dilutive effect from the issuance of new shares.
• Employees: This filing specifically relates to director compensation and does not directly impact the broader employee base, though it reflects the company's approach to equity incentives.

Next Steps

• The 8,500 Restricted Stock Units will vest on November 3, 2028, at which point they will convert into shares of TherapeuticsMD common stock.

Key Dates

Keywords

TherapeuticsMD, TXMD, Restricted Stock Units, RSU, Insider Transaction, Director Compensation, Equity Grant, SEC Form 4